Assessment

cobicistat

HIV-1 infection in adolescents aged 12 years and older (body weight ≥35 kg with atazanavir or ≥40 kg with darunavir) as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily within an antiretroviral combination therapy